MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Puma Biotechnology Inc

Suletud

SektorTervishoid

5.47 1.48

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.47

Max

5.54

Põhinäitajad

By Trading Economics

Sissetulek

2.9M

5.9M

Müük

6.4M

52M

P/E

Sektori keskmine

5.343

36.442

Kasumimarginaal

11.166

Töötajad

172

EBITDA

6.8M

11M

Soovitused

By TipRanks

Soovitused

Müü

12 kuu keskmine prognoos

-45.16% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. nov 2025

Turustatistika

By TradingEconomics

Turukapital

108M

266M

Eelmine avamishind

3.99

Eelmine sulgemishind

5.47

Uudiste sentiment

By Acuity

20%

80%

37 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. okt 2025, 18:13 UTC

Suurimad hinnamuutused turgudel

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17. okt 2025, 17:05 UTC

Suurimad hinnamuutused turgudel

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

17. okt 2025, 15:03 UTC

Suurimad hinnamuutused turgudel

Obook Shares Sink Following Public Debut

17. okt 2025, 14:41 UTC

Suurimad hinnamuutused turgudel

Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug

17. okt 2025, 23:25 UTC

Omandamised, ülevõtmised, äriostud

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17. okt 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17. okt 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17. okt 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17. okt 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. okt 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17. okt 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17. okt 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17. okt 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17. okt 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17. okt 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. okt 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17. okt 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17. okt 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17. okt 2025, 16:20 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

17. okt 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. okt 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17. okt 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17. okt 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17. okt 2025, 15:56 UTC

Tulu

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17. okt 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17. okt 2025, 15:43 UTC

Market Talk

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

17. okt 2025, 14:58 UTC

Market Talk

Small-Business Trepidation in Canada Points to Economic Decline -- Market Talk

17. okt 2025, 14:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. okt 2025, 14:35 UTC

Market Talk
Tulu

American Express's Delayed Card Fee Hike Worries Some Investors -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-45.16% langus

12 kuu keskmine prognoos

Keskmine 3 USD  -45.16%

Kõrge 4 USD

Madal 2 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

2 ratings

0

Osta

1

Hoia

1

Müü

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

37 / 371 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat